Compare Amplitude Inc (AMPL) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amplitude Inc vs Incyte Corporation — how do they compare? Amplitude Inc trades at $9.33 (market cap $1.22B), while Incyte Corporation trades at $114.92 (market cap $23.32B). The key difference: Incyte Corporation is far larger — about 19.1× Amplitude Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Amplitude Inc nearer its low. Which is the better fit depends on your goals.
| AMPL | INCY | |
|---|---|---|
Market Cap | $1.22B | $23.32B |
Sector | Technology | Health |
52-Week High | $13.04 | $118.52 |
52-Week Low | $5.61 | $67.38 |
Enterprise Value | $1.05B | $19.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPL trades at $9.18, down 2.13% over the past day, with a bullish technical signal from moving averages but bearish oscillators. Revenue growth is strong, reaching $343.21M in 2025, yet the company remains unprofitable with a net income margin of -25.11%. Analyst consensus is bullish with a $9.25 price target, though recent news includes multiple law firm fraud investigations and a Bank of America downgrade citing profitability concerns.
The outlook hinges on AMPL's ability to translate robust revenue growth into profitability amid competitive pressures. Investment opportunity lies in potential margin expansion and market share gains, but risks include ongoing legal scrutiny, execution challenges, and persistent negative cash flows. The stock's near-term direction will likely be driven by upcoming earnings results and clarity on the fraud allegations.
INCY trades at $116.71, down 1.53% on the day, with a bullish technical outlook supported by moving averages and strong fundamentals. The company reported robust revenue of $5.14 billion in 2025, with a net income margin of 26.71%, and recent news highlights regulatory approvals and portfolio expansion, including the acquisition of Vega Therapeutics.
The outlook is positive, driven by earnings beats, product pipeline advancements, and analyst consensus leaning buy. Key risks include execution of recent acquisitions and reliance on key products like Opzelura, but institutional sentiment remains strong with a consensus price target of $107.88.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amplitude Inc
Amplitude Inc is pioneering a new category of software called digital optimization. The company's digital optimization system serves as the command center for businesses to connect digital products to business outcomes.
Read more on AMPL →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
